13 Sept 2022 , 12:58 PM
The company has received final approvals for 5 mg, 10 mg, 15 mg, and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength.
Lenalidomide is a cancer treatment medication. It functions by slowing or preventing cancer cell proliferation. It's also used to treat anemia in those with blood/bone marrow abnormalities. The company will manufacture the medicine at the group's formulation manufacturing plant in Ahmedabad Special Economic Zone, India.
According to IQVIA MAT July 2022, lenalidomide had yearly sales of USD 2.86 billion in the United States. The product would be released in the United States soon. The group already has 322 approvals and has filed over 4 applications.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.